Table 2.
Univariate prognostic analysis of clinicopathologic parameters in 131 DLBCL patients
| Risk factors | n | 3-year OS (%) | 5-year OS (%) | P |
|---|---|---|---|---|
| Gender | ||||
| Male | 77 | 59.5 | 27.6 | 0.185 |
| Female | 54 | 47.7 | 32.5 | |
| Age | ||||
| > 60 | 49 | 42.7 | 30.5 | 0.036* |
| ≤ 60 | 82 | 68.0 | 27.9 | |
| Extranodal sites | ||||
| < 2 | 92 | 58.8 | 35.1 | 0.160 |
| ≥ 2 | 39 | 45.9 | 15.1 | |
| Clinical stage | ||||
| III-IV | 59 | 41.2 | 27.4 | 0.035* |
| I-II | 72 | 65.5 | 30.6 | |
| LDH level | ||||
| High | 51 | 39.2 | 17.6 | < 0.001* |
| Normal | 49 | 84.8 | 63.6 | |
| ECOG PS | ||||
| < 2 | 98 | 55.3 | 33.1 | 0.526 |
| ≥ 2 | 32 | 51.9 | 26.0 | |
| IPI score | ||||
| 3-5 | 47 | 31.4 | 19.6 | < 0.001* |
| 0-2 | 84 | 68.6 | 34.8 | |
| B symptoms | ||||
| Yes | 29 | 45.6 | 0.0 | 0.171 |
| No | 101 | 56.7 | 36.2 | |
| Hgb | ||||
| Low | 64 | 47.4 | 8.0 | 0.080 |
| Normal | 63 | 58.1 | 48.2 | |
| Subtype | ||||
| GCB | 38 | 70.1 | 52.7 | 0.031* |
| Non-GCB | 93 | 48.4 | 15.7 | |
| Treatment | ||||
| No | 53 | 37.6 | 13.7 | < 0.001* |
| Yes | 78 | 69.1 | 46.2 | |
| Chemotherapy | ||||
| R-CHOP | 39 | 74.0 | 74.0 | 0.101 |
| CHOP + other | 39 | 64.5 | 17.9 | |
| XPO1 | ||||
| + | 74 | 46.2 | 25.3 | 0.043* |
| - | 57 | 65.3 | 34.9 | |
| Bcl-2 | ||||
| + | 105 | 53.3 | 18.8 | 0.028* |
| - | 26 | 61.2 | 61.2 | |
| Ki67 | ||||
| + | 83 | 57.7 | 32.5 | 0.419 |
| - | 48 | 50.4 | 25.6 |
Annotation: DLBCL, diffuse large B-cell lymphoma; OS, overall survival; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; Hgb, hemoglobin; GCB, germinal center B cell-like; non-GCB, non-germinal center B cell-like; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP, rituximab, cyclophosphamide, daunorubicin, vincristine, prednisone; other chemotherapy including methotrexate or temozolomide;
*
P < 0.05.